Novel Route of Inhaled Insulin for Diabetes Treatment

Abstract

Diabetes is a chronic condition characterised by insufficient insulin secretion and hyperglycemia as a result. Microvascular and macrovascular disease are two types of diabetic complications that are affected by good diabetes management. Many diabetics rely on subcutaneous insulin injections or continuous infusions to keep their blood sugar levels under control. Insulin delivery via new routes Since the 1920s, subcutaneous insulin has been used to treat diabetes; nevertheless, despite a variety of formulations, intensive insulin therapy including many daily injections has not acquired universal clinical approval. The search for a successful, well-tolerated nonenteral method for delivering insulin began in the 1920s, and has included ocular, buccal, rectal, vaginal, and other routes. Given that insulin injection therapy is burdensome for many patients, novel insulin administration routes are of interest in the diabetes sector. The use of inhalation to administer insulin to the lungs will be discussed in this review. Inhaled insulin's safety as well as efficacy in contrast to subcutaneous insulin in diverse diabetic populations are discussed. Until recently, many researchers considered that noninvasively given insulin had too low a bioavailability to be useful in clinical practise. Inhaled insulin, on the other hand, appears to be an effective, well-tolerated, and noninvasive alternative to subcutaneous regular insulin, according to a growing body of research. Importantly, inhaled insulin has a more physiological insulin profile than injectable insulin.